Impact of the retest effect in the MIG-HD cohort.

<p>SDMT: Symbol Digit Modalities Test; Stroop C, W and C/W: Stroop color, word and color/word interference; MDRS: Mattis Dementia Rating Scale; TMT A, B: Trail-Making Test A and B; TFC: Total Functional Capacity; IS: Independence Scale; FAS: Functional Assessment Scale. The red curve represents the baseline (reference score A₁) and the blue curve shows the mean relative score one month later (A₂). The portion of the blue curve beyond the red curve indicates performance improvement between A₁ and A₂. Paired <i>t</i>-tests, significance: * <i>P</i><0.05, ** <i>P</i><0.01, *** <i>P</i><0.001.</p

Observed performance at one year (A₃), with A₁ or A₂ used as the baseline, in the MIG-HD cohort.

<p>SDMT: Symbol Digit Modalities Test; Stroop C, W and C/W: Stroop color, word and color/word interference; MDRS: Mattis Dementia Rating Scale; TMT A, B: Trail-Making Test A and B; TFC: Total Functional Capacity; IS: Independence Scale; FAS: Functional Assessment Scale. The red curve represents the baseline (reference score). The blue (or green) curve corresponds to the mean relative score one year later (A₃), with A₁ (or A₂ for the green curve) used as the baseline. A green curve within the blue curve indicates that the decline was easier to detect if A₂ was used as the baseline, rather than A₁. Paired <i>t</i>-tests, significance: * <i>P</i><0.05, ** <i>P</i><0.01, *** <i>P</i><0.001.</p

External validation of models in the RIL-HD cohort, based on <i>R</i>_<i>e</i>^<i>2</i> and ICC.

<p>SDMT: Symbol Digit Modalities Test; Stroop C, W and C/W: Stroop color, word and color/word interference; MDRS: Mattis Dementia Rating Scale; TMT A, B: Trail-Making Test A and B; HVLT: Hopkins Verbal Learning Task; TFC: Total Functional Capacity; IS: Independence Scale; FAS: Functional Assessment Scale. N: number of patients in the RIL-HD cohort for whom all the data required for the predictive model were available. <i>R</i>_<i>e</i>^<i>2</i>: coefficient of determination for external validation. ICC: intraclass correlation coefficient. 95% CI: 95% confidence interval. a: <i>R</i>_<i>e</i>^<i>2</i> = -0.7. The red line represents the limit for a high-quality model (<i>R</i>_<i>e</i>^<i>2</i> > 50% of the observed variance explained by the model).</p

Demographic and clinical characteristics of the HD patients and proxies.

<p>Data are numbers and means ± SD (<i>range</i>) unless otherwise indicated. N: numbers; UHDRS: Unified Huntington’s Disease Rating Scale [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0128209#pone.0128209.ref032" target="_blank">32</a>]; TFC: total functional capacity [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0128209#pone.0128209.ref022" target="_blank">22</a>]; MDRS: Mattis Dementia Rating Scale [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0128209#pone.0128209.ref023" target="_blank">23</a>].</p><p>Demographic and clinical characteristics of the HD patients and proxies.</p

Longitudinal analysis of information processing.

<p>Huntington’s disease patients (HD) and proxies had a similar understanding of the protocol at M0. Comprehension score decreased over time in the HD patients, whereas it remained stable in their proxies (Prox). Satisfaction with the information provided remained stable in both patients and proxies. Error bars represent standard errors.</p

Reasons for consenting: motivations and expectations.

<p>Patients and proxies were asked to classify each motivation as important or not important (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0128209#pone.0128209.s001" target="_blank">S1 File</a>). ns: not significant (<i>p</i> > 0.05; Fisher’s exact test).</p><p>Reasons for consenting: motivations and expectations.</p

Demographic, clinical and biological features of HD patients at baseline.

<p>Demographic, clinical and biological features of HD patients at baseline.</p

Mean baseline scores and annual slopes of cognitive assessments during the follow-up in the whole cohort.

<p>Mean baseline scores and annual slopes of cognitive assessments during the follow-up in the whole cohort.</p

Characteristics and evolution of the overall cohort and the groups of patients taking antipsychotics and related drugs.

<p>HD Huntington' disease; SDMT Symbol digit modality test.</p><p>n: available data; Baseline: Mean ± SD; Change per year: Mean ± SE.</p

Percentage of prescriptions made for each class of antipsychotic and related drugs (2002–2010).

<p>Aripiprazole and tetrabenazine obtained market authorisation in 2004 and 2005, respectively.</p